LOW GRADE SEROUS OVARIAN CANCER
Clinical trials for LOW GRADE SEROUS OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new LOW GRADE SEROUS OVARIAN CANCER trials appear
Sign up with your email to follow new studies for LOW GRADE SEROUS OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo takes on recurrent ovarian cancer
Disease control Recruiting nowThis study tests a new drug called ubamatamab, alone or with another drug (cemiplimab), in people with ovarian or uterine cancer that has come back. The main goals are to check safety, find the best dose, and see if the drugs can shrink tumors. About 890 participants will take pa…
Matched conditions: LOW GRADE SEROUS OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
New hope for rare ovarian cancer: drug combo targets tumor growth
Disease control Recruiting nowThis study tests whether a combination of two drugs (avutometinib and defactinib) works better than standard treatments for people with recurrent low-grade serous ovarian cancer. About 270 participants whose cancer returned after platinum-based therapy will be randomly assigned t…
Matched conditions: LOW GRADE SEROUS OVARIAN CANCER
Phase: PHASE3 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:53 UTC
-
Promising drug cocktail targets Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests a combination of three drugs (avutometinib, defactinib, and letrozole) in 20 women with low-grade serous ovarian cancer who cannot have surgery right away. The goal is to see if the drugs can shrink tumors or control the cancer. Researchers will also monitor side…
Matched conditions: LOW GRADE SEROUS OVARIAN CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 10, 2026 13:28 UTC